As using psychedelics as medicines for mental health conditions has become more popular, it has been an open question of whether substances such as psilocybin (magic mushrooms) can safely be combined with anti-depressants such as SSRIs.
Now, Compass Pathways (CMPS) has released a small study, which showed that it is in fact safe to combine the two drugs. This is the second such small study to come to this conclusion. Earlier this year, MindMed, (MNMD / MMED) had released data on a similar study, with similar results
However, it is important to note that these are two very small studies, and that nothing has been definitively proven yet.
Many argue that psychedelics like psilocybin should be a replacement for depression medications such as SSRIs, not another layer of medicine. While I am sympathetic to this view, we must ultimately follow the science.
Compass Pathways will use the results of this trial to inform the design of their upcoming phase 3 trial testing whether psilocybin can treat treatment resistant depression.
Follow us on social media! 🙌
Instagram: @thepsychedelicinvestor
Facebook: @thepsychedelicinvestor

Want to collaborate? Send us an email at:
thepsychedelicinvestor@gmail.com

Music from:
www.bensound.com

Video editing: @themyaholy
@Psychedelic Spotlight

#psychedelics #antidepressants #psilocybin

Similar Posts

Is MindMed the NEXT Tesla? (MindMed Bull Thesis)

Is MindMed the NEXT Tesla? (MindMed Bull Thesis)

Listen, Videos

Is MindMed (MMED / MMEDF) the next Tesla (TSLA)? It could be. In this video we give the bull case scenario for MindMed, and give a general company overview.

MindMed (MMED) is our favorite psychedelic stock by far, with trials using LSD to treat anxiety and ADHD, as well as their proprietary 18-MC compound to treat addiction.

Follow us on social media!
Instagram: @psychedelicinvestor
Facebook: @thepsychedelicinvestor

Music: www.bensound.com
â–º Music Credit: LAKEY INSPIRED
Track Name: “Blue Boi”
Music By: LAKEY INSPIRED @ https://soundcloud.com/lakeyinspired

Original upload HERE – https://www.youtube.com/watch?v=wAukv…
Official “LAKEY INSPIRED” YouTube Channel HERE – https://www.youtube.com/channel/UCOmy…
License for commercial use: Creative Commons Attribution 3.0 Unported “Share Alike” (CC BY-SA 3.0) License.
Full License HERE – https://creativecommons.org/licenses/…

Music promoted by NCM https://goo.gl/fh3rEJ

DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.

Links from studies and websites :
https://www.cdc.gov/nchs/pressroom/podcasts/20190911/20190911.htm?fbclid=IwAR3_UBSk2yv4lwOld0su1YpnJHsjPA4x5XK-X2pO5LMz1AeXiojkswcDV8Y#:~:text=Anestimated69029peopledied,wereduetoheroin

https://www.hhs.gov/opioids/about-the-epidemic/index.html?fbclid=IwAR0df0UXoVhfWf03RQNkP5OMInM5Nyxz6j68V5GXr5lv0lDUuRL_R-UL4ZA

https://www.camh.ca/en/health-info/mental-illness-and-addiction-index/opioid-addiction?fbclid=IwAR31PQiu49359xjhzD4sTgcicRQLGh-l95y2DuFihHPdql87eHTDnYsTELw

https://preprod.drugfree.org/article/relapse-overdose/?fbclid=IwAR1YSZEIUDCiYDeBIYCk1WhEA_NJCrjyyz56zteyrbGKhDYQtsu2X1fDVOM

https://www.drugabuse.gov/publications/drugs-brains-behavior-science-addiction/treatment-recovery?fbclid=IwAR2_c4gVhURANeU5pCc0k97Ba4ML-kYZIGOZvGfqpHmo8o4jdxZp0SEHyQQ

https://maps.org/research-archive/presentations/Brown_GITA_Vancouver_Oct2012_iboga_comm_rev.pdf

https://www.tandfonline.com/doi/full/10.1080/00952990.2017.1310218?fbclid=IwAR0OBK0eFJ64-v7gu1yE1TnyUIK1XhSDJvd_XLxhZaRtC4bWF8MfD0ine3M

https://www.healio.com/news/primary-care/20191205/ibogaine-treatment-for-opioid-use-disorder-what-you-need-to-know?fbclid=IwAR39o1sonUGLHsMGwH3pzbm3aAkU98P15CFNYaQX0r3VNQtJdSy3pazvRJM#

https://mindmed.co/psychedelic-inspired/?fbclid=IwAR1EK84fYX4WrObq45LkQfkZiW3ZtUYNsVZ4Y9q_wMHqas7y8IwoJmFyTBs#scroll_section-1

https://www.globenewswire.com/news-release/2020/02/20/1988216/0/en/Drug-Addiction-Treatment-Market-To-Reach-USD-31-17-Billion-By-2027-Reports-And-Data.html?fbclid=IwAR2ZeDBuW69x1DkczkxVRmadUBTpwu1Dilur64LkqBISH1Dqu8FC3EgFzmU

https://adaa.org/about-adaa/press-room/facts-statistics?fbclid=IwAR2YlG6rTd0jdUP3XIkm0t-_-QRYDyWDlVGh_sF6CZkayVEyGUZZpGcplwE#:~:text=Anxietydisordersarethemost,ofthosesufferingreceivetreatment

https://adaa.org/finding-help/treatment/medication?fbclid=IwAR10tRsqwdRMx-PqpKA9yx5BPGvNcVJRugkw3L6tq7DrDIO4gVdNwb6BGJ4

https://www.newswire.ca/news-releases/mindmed-receives-approval-of-protocol-design-to-evaluate-microdoses-of-lsd-for-adult-adhd-in-phase-2a-clinical-trial-from-swiss-and-dutch-health-authorities-897700369.html?fbclid=IwAR0jnNn2wDJocJEkfVGMtC1idTsBdupLZw-VQ0ddJskemRH0B8d50ykq0ng

https://maps.org/research-archive/lsd/Gasser-2014-JMND-4March14.pdf

https://www.smartpatients.com/trials/NCT03153579?fbclid=IwAR0df0UXoVhfWf03RQNkP5OMInM5Nyxz6j68V5GXr5lv0lDUuRL_R-UL4ZA

https://www.marketwatch.com/press-release/global-anxiety-disorders-and-depression-treatment-market-2020-research-report-with-consumption-revenue-opportunities-market-share-and-growth-rate-covid-19-impact-and-forecast-to-2026-absolute-reports-2020-11-06?fbclid=IwAR1jEtR6h9mTPla8OzW5RiIW2ecf_HnrT7of42bU4mO5dsfpxxuCAFv-7bE

https://www.additudemag.com/statistics-of-adhd/?fbclid=IwAR1mQaSVujUayYXwzCQRryiCZzM4gckjKAbg5O9H5BwCJIUbrXypOlgU4qM#:~:text=About6.1millionchildrenin,ControlandPrevention(CDC)

https://www.additudemag.com/adhd-medication-for-adults-and-children/?fbclid=IwAR0jnNn2wDJocJEkfVGMtC1idTsBdupLZw-VQ0ddJskemRH0B8d50ykq0ng

https://www.floridarehab.com/drugs/meth/related/meth-vs-adderall/?fbclid=IwAR0WbOJtUIMcW4sPsQ7TUR-ulrPC9rwa1b2_KxHw_lFJBk_ygesCtsQJqDs

https://www.drugwatch.com/adderall/side-effects/?fbclid=IwAR3_UBSk2yv4lwOld0su1YpnJHsjPA4x5XK-X2pO5LMz1AeXiojkswcDV8Y

https://drug-dev.com/adhd-treatment-market-value-to-reach-9-9-billion/?fbclid=IwAR0jnNn2wDJocJEkfVGMtC1idTsBdupLZw-VQ0ddJskemRH0B8d50ykq0ng

https://mindmed.co/team/

#MindMed #MMED #Mindmedstock #Tesla #TSLA #PsychedelicStocks #ThePsychedelicInvestor

Atai Life Sciences, Compass Pathways, MindMed & Cybin’s Q3 Financial Results Analysis – What’s Next?

Atai Life Sciences, Compass Pathways, MindMed & Cybin’s Q3 Financial Results Analysis – What’s Next?

Learn, Videos

Analyzing the Quarter 3 financial results of atai Life Sciences (Nasdaq: ATAI), Compass Pathways (Nasdaq: CMPS), MindMed (Nasdaq: MNMD) and Cybin (NYSE: CYBN).

It’s earning season! In this episode we compare and contrast the financials of the four biggest companies in the psychedelic medicines space, atai, Compass Pathways, MindMed and CYBIN. All four released their Q3 financials in the past week. All four are the biggest psychedelic stocks
We also look at some of the highlights of the past quarter for each company, and do some rough back of the napkin math to determine when they will need to raise more capital.

Atai Life Sciences (atai stock) is the best financed company, and had a very eventful quarter. They started clinical trials studying r-ketamine, ibogaine, a schizophrenia drug and more.
Compass Pathways (CMPS stock), the next best financed psychedelics company, released the results of their long awaited Comp 360 phase 2b clinical trial, testing treating Treatment-Resistant Depression with psilocybin. They also announced a new trial using comp 360 to treat PTSD, hired the famous Hamilton Morris, and acquired an IP portfolio of novel medicines.

MindMed (MNMD Stock) had a quieter quarter, though it was still impressive. Despite having over a hundred million dollars in the bank, since they are spending so much on their million projects, they will likely have to raise capital through dilution within a year. Their work with LSD, 18-MC Psilocybin and more continues in the background, but this quarter was all about hiring talent.

Cybin (CYBN stock) is in a bigger cash crunch, only having enough capital for roughly a year. This means they will almost certainly be raising capital soon. Despite this, they had a great quarter and announced that their lead drug candidate CYB-003, a modified version of psilocybin, shows great promise in animal models.

Links:
Atai: https://www.atai.life/2021/11/05/atai-life-sciences-reports-third-quarter-2021-financial-results-and-corporate-update/
Compass Pathways: https://compasspathways.com/financial-results-and-business-highlights-for-the-third-quarter-2021/

MindMed:
https://www.prnewswire.com/news-releases/mindmed-announces-financial-results-for-the-third-quarter-2021-and-business-highlights-cash-balance-of-145-9-usd-185-4-cad-to-execute-on-diverse-clinical-pipeline-301423844.html
Cybin:

https://www.businesswire.com/news/home/20211115005552/en/Cybin-Inc.-Reports-its-Second-Quarter-Financial-Results-and-Recent-Business-Highlights

Enjoy the episode!
Follow us on social media!
Instagram: @thepsychedelicinvestor
Facebook: @thepsychedelicinvestor
James’ Twitter: @Psy_Invest
Maria’s Twitter (Producer & Editor): @Psy_Holy

Want to collaborate? Send us an email at:
thepsychedelicinvestor@gmail.com

Music from:
www.bensound.com
Video editing: @themyaholy

DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.

#ataiLifeSciences #MindMed #Cybin

Doug Drysdale On How CYB-003 Is Better Than Psilocybin

Doug Drysdale On How CYB-003 Is Better Than Psilocybin

Listen, Podcasts

In this episode, James Hallifax from the Psychedelic Investor, interviews Doug Drysdale, CEO of Cybin (NYSE: CYBN). In this fantastic discussion, Doug and James discuss the potential for psilocybin (magic mushrooms) to treat depression and other mental health issues.

Does Microdosing Mushrooms Work? ( Interview with Sena Maria)

Does Microdosing Mushrooms Work? ( Interview with Sena Maria)

Listen, Videos

Hello Psychedelic Investors! The topic of today’s video is “Does microdosing mushrooms work?” We usually talk about investing in psychedelic stocks and companies inspired by microdosing psychedelics with the mission to cure depression, anxiety, adhd, etc. But we never really dove deep into the science of microdosing. Does Microdosing Magic Mushrooms really work? So before investing in companies like MindMed (MMED/MMEDF), Compass Pathways (CMPS), Numi, Field Trip Health (FTRP) or Atai Life Sciences, listening to someone who’s got a personal experience with psychedelics might not be such a bad idea.

One of the reasons behind the interview with pro in the Microdosing psilocybin realm is that recent studies have shown that the benefits of microdosing can be attributed completely to placebo effects. That’s why I decided to have a talk with Sena Maria. Sena is passionate about working with the fungi realm to support our collective evolution. Coming from Google in Silicon Valley she took a big life pivot and has spent the last 5 years learning from the plants. After supporting hundreds of people in getting started with microdosing, she now shares what she’s learned on her YouTube channel The Medicine of Being Human and her instagram @sena__maria.

So what do you guys think? Is Microdosing Psychedelics the Future of Medicine? Hopefully some of the new MMED or CMPS or any other psychedelic stocks investors got some value in this! What do you guys think?

You can learn more about microdosing in her popular webinar Microdosing For Resilience at www.medicineofbeinghuman.com

Timestamps:

0:00 – Intro
1:11 – What is Microdosing & How does it Work?
2:55 – Microdosing Benefits
7:28 – Why Microdosing? ( Regimen & Protocols)
14:12 – Discussing microdosing & placebo effects
19:21 – Personal Microdosing Experiences & Consistency
24:09 – Microdosing Advice for Beginners

#PsychedelicStocks #MindMed #MicrodosingPsilocybin

Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!

Follow us on social media! 🙌
Instagram: @psychedelicinvestor
Facebook: @thepsychedelicinvestor
Music: www.bensound.com

DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.